Full-Time
Field Application Scientist
Maravai LifeSciences
51-200 employees
Offers oligonucleotide synthesis and immunohistochemistry
Compensation Overview
$85k - $100k/yr
Boston, MA, USA
Remote
Remote role with travel of up to 30% for customer meetings, conferences, presentations, and commercial activities.
PhD
 Biology & Biotech (1) |
|---|
Get referred to Maravai LifeSciences
See people who can refer or advise you
- A Ph.D. in Molecular Biology, Biochemistry, Chemistry, Genomics, or a related scientific discipline with 0–2 years of relevant experience; or a bachelor's degree with 8+ years or a master's degree with 6+ years of relevant experience; or an equivalent combination of education and experience.
- Demonstrated knowledge and hands-on experience in one or more relevant areas, such as guide RNA, oligonucleotide synthesis, mRNA technologies, nucleic acid therapeutics, molecular biology, or related scientific applications.
- Experience supporting scientific product development, custom manufacturing, analytical testing, process development, GMP services, quality, or related technical functions.
- Demonstrated ability to assess technical requirements, analyze scientific information, troubleshoot applications, and develop practical customer-focused recommendations.
- Strong customer-facing, consultative, presentation, and scientific communication skills with the ability to translate complex scientific concepts for technical and non-technical audiences.
- Demonstrated ability to collaborate effectively across Business Development, Commercial, Product Management, Research and Development, Manufacturing, and Quality organizations.
- Willingness to travel up to 30% to support customer meetings, conferences, scientific presentations, and commercial activities.
- Partner with Business Development and Commercial teams to provide scientific and technical support for customer opportunities, custom solutions, and pre- and post-sales activities.
- Develop scientific recommendations for guide RNA, oligonucleotide, mRNA, custom manufacturing, analytical testing, and phase-appropriate GMP services based on customer requirements and product capabilities.
- Serve as a scientific resource to customers by addressing technical questions, troubleshooting applications, and providing guidance on TriLink technologies, products, and services.
- Assess customer requirements and collaborate with Product Management, Research and Development, Manufacturing, Quality, and Commercial teams to evaluate technical feasibility and identify appropriate solution approaches.
- Represent TriLink through customer meetings, scientific presentations, webinars, workshops, conferences, and industry events while communicating technical information clearly and effectively.
- Capture and communicate Voice of the Customer, emerging applications, scientific literature, and market trends to support product improvements, customer applications, and commercial initiatives.
- Prepare and present technical proposals, statements of work, scientific presentations, webinars, application materials, and other customer-facing technical documentation.
- Knowledge of clinical development, CMC, GMP, or regulatory considerations supporting nucleic acid therapeutics.
Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2014
Get referred to Maravai LifeSciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 2026 revenue rose 40.5% to $65.8 million, and guidance increased.
- Q2 2026 revenue reached $51.4 million, while adjusted EBITDA rose to $8.7 million.
- Refinancing extended debt maturity to 2032, giving Maravai flexibility for 2026 investments.
What critics are saying
- Maravai’s February 2025 revenue-restatement scandal exposed internal-control failures and goodwill issues.
- The August 2025 restructuring cut 25% of staff, risking execution gaps through Q3 2026.
- COVID CleanCap demand remains volatile; a sustained drop destroys TriLink’s growth engine.
What makes Maravai LifeSciences unique
- TriLink’s July 20, 2026 CleanCap patents secure dominant mRNA capping IP globally.
- Cygnus’s mock viral particle technology shields bioprocess testing from direct reagent commoditization.
- Officinae Bio’s February 24, 2025 acquisition adds AI-enabled mRNA design to TriLink.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Company Equity
Fertility Treatment Support
Family Planning Benefits
401(k) Retirement Plan
Paid Vacation
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...
SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...
The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.
Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.
Maravai LifeSciences, a global provider of life science reagents and services, reported first quarter 2026 revenue of $65.8 million, up 40.5% year-over-year, driven by strong demand in its TriLink business. The company posted a net loss of $6.4 million but achieved adjusted EBITDA of $20.3 million and returned to positive free cash flow, generating $4.2 million. TriLink revenue grew 65% to $47.5 million, including $14.3 million from COVID vaccine programme orders. Excluding COVID-related sales, TriLink base revenue increased 15% year-over-year. Cygnus revenue rose 1.4% to $18.4 million. Following the strong performance, Maravai raised its full-year 2026 guidance, now expecting revenue of $205 million to $215 million and adjusted EBITDA of $30 million to $32 million.